Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-616-2 | CAS number: 123-30-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Genetic toxicity: in vivo
Administrative data
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2006/08/31-2007/10/04
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Guideline study under GLP condition
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 007
- Report date:
- 2007
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- JAPAN: Guidelines for Screening Mutagenicity Testing Of Chemicals
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- micronucleus assay
Test material
- Reference substance name:
- 4-aminophenol
- EC Number:
- 204-616-2
- EC Name:
- 4-aminophenol
- Cas Number:
- 123-30-8
- Molecular formula:
- C6H7NO
- IUPAC Name:
- 4-aminophenol
- Details on test material:
- - Physical state: slightly brown crystalline powder
- Analytical purity: 99.9%
- Lot/batch No.: LTQ5219 (Wako Pure Chemical Industries, Ltd.)
- Storage condition of test material: in the cool and dark space(3 - 7℃)
:
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- CD-1
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Japan, Inc.
- Age at study initiation: 8 weeks old
- Weight at study initiation: Males: 32.3 - 35.9 g
- Housing: Animals were individually housed in plastic cage.
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 8days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 - 25 ℃
- Humidity (%): 42 - 59%
- Air changes (per hr): 10 - 15 times/hr
- Photoperiod (hrs dark / hrs light): 12 hrs dark /12 hrs light
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- - Vehicle(s)/solvent(s) used: 0.5 %CMC (carboxymethyl cellulose)-Na
- Duration of treatment / exposure:
- 1 day
- Frequency of treatment:
- once
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
0, 125, 250, 500 mg/kg
Basis:
actual ingested
- Remarks:
- Doses / Concentrations:
Basis:
- No. of animals per sex per dose:
- 6 males/dose
- Control animals:
- yes, concurrent vehicle
- Positive control(s):
- Mitomycin C
- Route of administration: i.p.
- Doses / concentrations: 1 mg/kg bw (0.1 mg/ml)
Examinations
- Statistics:
- Statistical analyses were conducted by Kastenbaum & Bowman's statistical table, Cochran-Amitage test, student's t-test
Results and discussion
Test results
- Sex:
- male
- Genotoxicity:
- positive
- Toxicity:
- yes
- Vehicle controls validity:
- valid
- Negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- RESULTS OF RANGE-FINDING STUDY
- Dose range: 0, 250, 500, 1000, 2000 mg/kg
- Toxicological findings in test animals:
Mortality: 1000 mg/kg (Male:8/9, Female:7/9), 2000 mg/kg (Male:8/9, Female:7/9)
Clinical sign: Orange brown urine(male/female: >=250 mg/kg), Cyanosis(male: 1000 mg/kg, female: 500, 1000, 2000 mg/kg)
Body weight changes: Decreased body weight or inhibition of body weight gain (male: 250, 500 mg/kg, female: 250, 500, 1000, 2000mg/kg)
- Induction of micronuclei:
Examination periods: at a 24, 48 and 72 h after administration.
The frequency of micronucleated polychromatic erythrocytes was significantly increased in males and females at a 24 h after administration.
- Ratio of PCE/NCE:
Inhibition of bone marrow cell proliferation was observed at a dose of 500 mg/kg at a 24 and 48h after administration.
RESULTS OF DEFINITIVE STUDY (See Table1)
- Induction of micronuclei:
The frequency of micronucleated polychromatic erythrocytes was significantly increased in males at a dose of 125 mg/kg and above.
- Ratio of PCE/NCE:
Examination periods: at a 24h after administration.
Inhibition of bone marrow cell proliferation was observed at a dose of 125 mg/kg and above under the test conditions.
Any other information on results incl. tables
Table 1. Observation of bone marrow smears (about 24 hours after administration)
Group | Animal No. | MNPCE/PCE (%) | PCE/ERY (%) |
Vehicle control | 1001 | 1 (0.05) | 89 (44.5) |
1002 | 3 (0.15) | 112 (56.0) | |
1003 | 1 (0.05) | 112 (56.0) | |
1004 | 3 (0.15) | 143 (71.5) | |
1005 | 2 (0.10) | 110 (55.0) | |
1006 | 2 (0.10) | 120 (60.0) | |
Mean ± S.D.(%) | 2 ± 1 | 114 ± 17 | |
%(Mean ± S.D.) | 0.10 ± 0.04 | 57.2 ± 8.7 | |
125 mg/kg | 2001 | 24 (1.20) | 71 (35.5) |
2002 | 23 (1.15) | 109 (54.5) | |
2003 | 25 (1.25) | 62 (31.0) | |
2004 | 14 (0.70) | 109 (54.5) | |
2005 | 23 (1.15) | 96 (48.0) | |
2006 | 21 (1.05) | 80 (40.0) | |
Mean ± S.D.(%) | 22 ± 4 | 88 ± 20 | |
%(Mean ± S.D.) | 1.08 ± 0.20a),b) | 43.9 ± 9.9*c) | |
250 mg/kg | 3001 | 19 (0.95) | 79 (39.5) |
3002 | 21 (1.05) | 89 (44.5) | |
3003 | 29 (1.45) | 79 (39.5) | |
3004 | 34 (1.70) | 106 (53.0) | |
3005 | 22 (1.10) | 59 (29.5) | |
3006 | 12 (0.60) | 52 (26.0) | |
Mean ± S.D.(%) | 23 ± 8 | 77 ± 20 | |
%(Mean ± S.D.) | 1.140 ± .39a),b) | 38.7 ± 9.9**c) | |
500 mg/kg | 4001 | 25 (1.25) | 79 (39.5) |
4002 | 20 (1.00) | 65 (32.5) | |
4003 | 24 (1.20) | 61 (30.5) | |
4004 | 24 (1.20) | 75 (37.5) | |
4005 | 18 (0.90) | 66 (33.0) | |
4006 | 21 (1.05) | 59 (29.5) | |
Mean ± S.D.(%) | 22 ± 3 | 68 ± 8 | |
%(Mean ± S.D.) | 1.10 ± 0.14a),b) | 33.8 ± 3.9**c) | |
Positive control (Mytomycin C: 1mg/kg) |
5001 | 52 (2.60) | 84 (42.0) |
5002 | 52 (2.60) | 100 (50.0) | |
5003 | 17 (0.85) | 100 (50.0) | |
5004 | 55 (2.75) | 102 (51.0) | |
5005 | 37 (1.85) | 114 (57.0) | |
5006 | 16 (0.80) | 84 (42.0) | |
Mean ± S.D.(%) | 38 ± 18 | 97 ± 12 | |
%(Mean ± S.D.) | 1.91 ± 0.90a) | 48.7 ± 5.8 |
MNPCE: Micronucleated polychromatic erythrocytes
PCE: Polychromatic erythrocytes
ERY: Erythrocytes
a): Statistically significant increase from the vehicle control value (Kastenbaum & Bowman's statistical table, P<0.05)
b): Dose-dependency by Cochran-Amitage test, P<0.01
c): Statisyically significant difference from the vehicle control value (student's t-test, *: P<0.05; **: P<0.01)
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): positive
- Executive summary:
4-aminophenol was administeed orall at doses of 125, 250 and 500 mg/kg and at 24 hours after the administration, bone marrow smear specimens were prepared. Sodium CMC aqueous solution of 0.5% w/v% and 1 mg/kg of mitomycin C were used for a negative convrol and a positive control, respectively.
The occurrence frequency of immature erthrocyes having a micronucleus increased was statistically significant in the groups administered with the test compound compared to the negative control group and was also dose-dependent. Additionally, the percentage of immature erythrocytes per 200 erythrocytes was significnatly decreased in the test article groups compared to the negative control group which was considered to be caused by the test article causing suppressive effects at these doses on bone marrow cell growth. The occurrence frequency of immature erythrocytes having a micronucleus in the negtive and positive controls was within the range of the the historical background of the laboratory, indicating the validity of the test result.
Based on these data, 4 -aminophenol was judged capable of inducing chromosomal aberrations in vivo in bone marrow cells of Crlj:CD1(ICR)(SPF) strain mice under the conditions in this study.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
På den här webbplatsen används kakor. Syftet är att optimera din upplevelse av den.